Redeye comments on OncoZenge’s announcement that SAFE has approved its SEK30.2m investment agreement with Yangtian Pharma, marking a critical step in securing funding for the pivotal phase III trial of BupiZenge. We see this as an important milestone that improves the company’s financial outlook and supports continued operational progress.
